Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Boehringer Ingelheim

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
From Boehringer Ingelheim
Via GlobeNewswire
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
From Boehringer Ingelheim
Via GlobeNewswire
Boehringer Ingelheim expands cancer research at its Vienna site
From Boehringer Ingelheim
Via GlobeNewswire
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
From Boehringer Ingelheim
Via GlobeNewswire
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
From Boehringer Ingelheim
Via GlobeNewswire
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results
From Boehringer Ingelheim
Via GlobeNewswire
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
From Boehringer Ingelheim
Via GlobeNewswire
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
From Boehringer Ingelheim
Via GlobeNewswire
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
From Boehringer Ingelheim
Via GlobeNewswire
Boehringer Ingelheim produces its own green energy
From Boehringer Ingelheim
Via GlobeNewswire
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
From Boehringer Ingelheim
Via GlobeNewswire
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
From Boehringer Ingelheim
Via GlobeNewswire
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
From Boehringer Ingelheim
Via GlobeNewswire
Less than half of veterinary professionals feel their profession is appreciated
From Boehringer Ingelheim
Via GlobeNewswire
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
From Boehringer Ingelheim
Via GlobeNewswire
SPEVIGO® approved for expanded indications in China and the US
From Boehringer Ingelheim
Via GlobeNewswire
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
From Boehringer Ingelheim
Via GlobeNewswire
New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses
From Boehringer Ingelheim
Via GlobeNewswire
Boehringer expands production site in Greece for new medicine
From Boehringer Ingelheim
Via GlobeNewswire
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
From Boehringer Ingelheim
Via Business Wire
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
From Boehringer Ingelheim
Via Business Wire
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
From Boehringer Ingelheim
Via Business Wire
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
From Boehringer Ingelheim
Via Business Wire
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
From Boehringer Ingelheim
Via Business Wire
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
From Boehringer Ingelheim
Via Business Wire
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
From Boehringer Ingelheim
Via Business Wire
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
From Boehringer Ingelheim
Via Business Wire
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
From Boehringer Ingelheim
Via Business Wire
Mental health focus makes Boehringer Ingelheim stand out as Global Top Employer 2023
From Boehringer Ingelheim
Via Business Wire
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
From Boehringer Ingelheim
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.